SpliceBind: 异构体感知的结合口袋可药性预测
SpliceBind: Isoform-Aware Prediction of Binding Pocket Druggability
AI总结:
提出图神经网络框架SpliceBind,通过异构体感知预测可药性,揭示结构方法成功与失败的边界,并建立耐药性分类法以指导临床决策。
摘要:
剪接介导的药物耐药性发生在高达40%的靶向激酶抑制剂患者中,然而最先进的可药性工具基于单一结构运行,无法跨异构体进行比较。我们引入SpliceBind,一个用于异构体感知可药性预测的图神经网络框架。除了提高预测准确性(AUROC 0.703 vs. P2Rank 0.634,p = 0.026),我们还解决了一个更基本的问题:结构方法何时成功,何时必然失败?对跨越五种机制类别的六个临床验证变体的系统分析揭示了一个双层耐药性分类法。结构域缺失(AR-V7,Delta = -18.39)和口袋破坏产生结构可检测的变化,而变构机制(BRAF-p61)仍然从根本上对任何口袋中心方法不可见——这是任何算法改进都无法跨越的边界。值得注意的是,学习到的嵌入捕获了仅靠几何结构无法识别的基于亲和力的耐药性(ALK-L1196M:Delta_SB = -0.228 vs. Delta_P2Rank = -0.95),部分弥合了结构-生化差距。在跨越25个家族的229个激酶口袋上,SpliceBind实现了AUROC 0.703(p = 0.026 vs. P2Rank),并对保留的家族具有稳健的泛化能力(AUROC 0.761)。这种分类法改变了临床工作流程:在发现剪接变体后,临床医生可以立即确定计算分诊是否足够,或者是否需要生化验证——从而缩短从变体发现到治疗决策的时间。
英文摘要:
Splice-mediated drug resistance occurs in up to 40% of patients on targeted kinase inhibitors, yet state-of-the-art druggability tools operate on single structures and cannot compare across isoforms. We introduce SpliceBind, a graph neural network framework for isoform-aware druggability prediction. Beyond improving prediction accuracy (AUROC 0.703 vs. P2Rank 0.634, p = 0.026), we address a more fundamental question: when do structural methods succeed, and when must they fail? Systematic analysis of six clinically validated variants spanning five mechanism classes reveals a two-tier resistance taxonomy. Domain deletions (AR-V7, Delta = -18.39) and pocket disruptions produce structurally detectable changes, while allosteric mechanisms (BRAF-p61) remain fundamentally invisible to any pocket-centric approach -- a boundary no algorithmic improvement can cross. Notably, learned embeddings capture affinity-based resistance missed by geometry alone (ALK-L1196M: Delta_SB = -0.228 vs. Delta_P2Rank = -0.95), partially bridging the structural-biochemical gap. On 229 kinase pockets spanning 25 families, SpliceBind achieves AUROC 0.703 (p = 0.026 vs. P2Rank) with robust generalization to held-out families (AUROC 0.761). This taxonomy transforms clinical workflows: upon discovering a splice variant, clinicians can immediately determine whether computational triage suffices or biochemical validation is required -- reducing time from variant discovery to therapeutic decision.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。